Chugai Pharmaceutical Co., Ltd. (CHGCY) Stock Price & Analysis
Chugai Pharmaceutical Co., Ltd. (CHGCY) is trading at USD 21.56, up 1.89% today, as of October 23, 2026 at 16:17 UTC (US market open; quotes may be delayed), according to Nexqual market data.
CHGCY last closed at USD 21.16; today's session has ranged USD 21.36–21.57 on volume of 5,853 shares. Market capitalization is $70.96B, with a 52-week range of USD 18.33–34.84 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CHGCY.md
Key facts (CHGCY)
- Analysts: None.
- Total return with dividends: 1Y -8.5% vs S&P 500 +14.6%; 5Y +18.4% vs S&P 500 +77.3%.
- Next earnings: 2026-10-27, EPS estimate USD —, revenue estimate $349B.
Analysts (CHGCY)
Consensus None.
Total return (dividends reinvested) (CHGCY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -8.5% | +18.4% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | -8.5% | +3.5% |
| Volatility (annualized) | 39.9% | 34.5% |
| Max drawdown | -43.2% (Feb 2026→Oct 2026) | -43.2% (Feb 2026→Sep 2026) |
CHGCY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $349.46B | — |
| Next quarter (ends Dec 2026) | — | — | — | $369.19B | — |
| Current fiscal year (ends Dec 2026) | — | — | — | $1.38T | — |
| Next fiscal year (ends Dec 2027) | — | — | — | $1.52T | — |
Key Statistics (as of October 23, 2026 at 16:39 UTC)
| Price | USD 21.56 |
|---|---|
| Change | ▲ 1.89% (up) |
| Previous Close | USD 21.16 |
| Open | USD 21.36 |
| Day Range | USD 21.36 – 21.57 |
| 52-Week Range | USD 18.33 – 34.84 |
| Volume | 5,853 shares |
| Market Cap | $70.96B |
| Exchange | PNK |
Technical Analysis (CHGCY)
Nexqual's technical model rates CHGCY "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of October 23, 2026 at 16:39 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 69.29 (neutral) |
| vs SMA50 | Above (USD 20.75) |
| MACD | 0.04 (positive) |
Analyst Ratings (CHGCY)
Wall Street analysts rate CHGCY "None", per Nexqual as of October 23, 2026 at 16:39 UTC.
| Consensus Rating | None |
|---|
Earnings (CHGCY)
| Next Earnings Date | 2026-10-27 |
|---|---|
| Revenue Estimate | $349.46B |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financials & Fundamentals (CHGCY)
| Total Revenue | $1.34T |
|---|---|
| Revenue Growth (latest quarter, YoY) | +17.80% |
| Gross Margin | +71.34% |
| Operating Margin | +47.09% |
| Profit Margin | +35.10% |
| ROE | +23.49% |
| Current Ratio | 4.35 |
| Total Cash | $962.57B |
| Total Debt | $0 |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financial Health Score (CHGCY)
Nexqual rates Chugai Pharmaceutical Co., Ltd.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 16:39 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 47% (last 12 months) |
| Balance Sheet | Mixed — JPY 962.6B cash, no debt |
| Cash Flow | Solid — Operating cash flow JPY 449.3B (TTM) |
| Efficiency | Strong — ROE 23%, ROA 17.1% |
Ownership (CHGCY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.05% |
| Shares Outstanding | 3.29B |
| Float | 1.28B |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Leadership (CHGCY)
Chugai Pharmaceutical Co., Ltd. is led by Osamu Okuda, President, CEO & Chairman, per Nexqual as of October 23, 2026 at 16:39 UTC.
| President, CEO & Chairman | Osamu Okuda |
|---|---|
| Senior Executive Officer, CFO, Head of Finance & Director | Iwaaki Taniguchi |
| Executive Vice President | Shinji Hidaka |
| Executive Vice President | Tetsuya Yamaguchi |
| Executive Vice President | Yoshiyuki Yano |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNY | Sanofi | USD 41.48 | ▼ 1.14% |
| GSK | GSK plc | USD 50.61 | ▼ 1.17% |
| BMY | Bristol-Myers Squibb Company | USD 61.75 | ▼ 1.98% |
| BIIB | Biogen Inc. | USD 250.76 | ▼ 1.21% |
| PFE | Pfizer, Inc. | USD 30.08 | ▼ 1.12% |
| NVO | Novo Nordisk A/S | USD 39.01 | ▼ 1.08% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt